Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Pediatric Patients |
Cho, So Yeon
(College of pharmacy & Division of Life and Pharmaceutical Sciences)
Kang, Wonku (College of pharmacy, Chungang University) Yee, Jeong (College of pharmacy & Division of Life and Pharmaceutical Sciences) Kim, Jae Youn (Department of pharmacy, Asan Medical Center) An, Sook Hee (College of pharmacy, Wonkwang University) Gwak, Hye Sun (College of pharmacy & Division of Life and Pharmaceutical Sciences) |
1 | Horwitz ME. Stem-cell transplantation for inherited immunodeficiency disorders. Pediatr Clin North Am 2000;47(6):171-87. DOI |
2 | Patzer L, Kentouche K, Ringelmann F, Misselwitz J. Renal function following hematological stem cell transplantation in childhood. Pediatr Nephrol 2003;18(7):623-35. DOI |
3 | Baird K, Cooke K, Schultx KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am 2010;57(1):297-322. DOI |
4 | Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40(10):935-44. DOI |
5 | Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplant 2008;41(2):215-21. DOI |
6 | Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24(6):472-95. DOI |
7 | Del Mar Fernandez De Gatta M. Immunosuppressive therapy for pediatric transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 2002;41(2):115-35. DOI |
8 | Dupuis LL, Taylor T, Saunders EF. Disposition of two oral formulation of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. Pharmacotherapy 2006;26(1):15-22. DOI |
9 | Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17(6):642-54. DOI |
10 | Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clin Pharmacokinet 2000;39(2):117-25. DOI |
11 | Pal Falck. A population pharmacokinetic model of cyclosporin applicable for assisting dose management of kidney transplant recipients. Clin pharmacokinet 2009;48(9):615-23. DOI |
12 | Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007;29:96-102. DOI |
13 | Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM. Ther Drug Moni 2004;26(1):23-30. DOI |
14 | Sun B, Li XY, Gao JW, et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplantation recipients. Ther Drug monit 2010;32(6):715-22. DOI |
15 | Fanta S, Jonsson S, Backman JT, Karlsson M.O, Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007;64(6):772-84. DOI |
16 | Willemze AJ, Cremers SC, Schoemaker RC, et al. Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol 2008;66(4):539-45. DOI |
17 | Jacobson PA, Ng J, Green KG, et al. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Bio Blood Marrow Transplantation 2003;9(5): 304-11. DOI |
18 | Kim SH, Kim KI, Yun HY, et al. Population pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation in leukemic patients. Korean J Clin Pharm 2010;20(1):9-16. |